Syngene International has announced a major extension of its long-standing strategic collaboration with Bristol Myers Squibb, strengthening their partnership through 2035. The expanded agreement significantly broadens the scope of integrated services across the entire drug development lifecycle, reinforcing Syngene’s role as a global contract research, development, and manufacturing organization (CRDMO).
Under the renewed collaboration, Syngene will provide end-to-end capabilities spanning discovery research, including chemistry, biology, drug metabolism and pharmacokinetics, along with translational sciences, pharmaceutical development, manufacturing, clinical trials support, and advanced data and information technology services. This integrated approach is designed to ensure seamless progression from early-stage research to commercialization, supporting Bristol Myers Squibb’s global innovation pipeline.
The partnership between Syngene and Bristol Myers Squibb dates back to 1998 and reached a key milestone with the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC). Fully commissioned in 2009, BBRC became Syngene’s first dedicated R&D center and has since evolved into a critical strategic research hub for Bristol Myers Squibb.
Today, BBRC houses around 700 Syngene scientists who work as an extension of Bristol Myers Squibb’s global research organization. The center supports integrated capabilities across target identification, lead discovery, lead optimization, pharmaceutical development, molecular and cell biology, protein sciences, assay biology, and clinical biomarkers. Its work spans multiple therapeutic areas, including cardiovascular diseases, fibrosis, immunology, and oncology.
Since its inception, BBRC has played a pivotal role in accelerating the advancement of novel compounds from early discovery to first-in-human studies. By enabling faster transitions across development stages, the collaboration has helped reduce both development timelines and overall costs for Bristol Myers Squibb.